1974–2023

Mainstreaming and Evidence-Based Integrative Medicine

Researchers pursued evidence-based integration by evaluating acupuncture and traditional Chinese medicine through systematic reviews, rigorous trial designs, and mechanistic studies. Ethnopharmacology and ethnobotanical documentation cataloged medicinal plants while pharmacology investigations addressed herb-drug interactions, safety, and phytochemical profiles. Global population studies mapped cross-cultural usage patterns, pediatric care dynamics, and oncology integration challenges. Public health responses and pandemic management further propelled the clinical investigation of herbal adjuvants and immunomodulatory plants.

Period 1974-2002: Researchers evaluated acupuncture, herbal pharmacology, and oncology patterns using systematic reviews, clinical trials, and epidemiological assessments[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. Seminal ethnographies, mindfulness protocols, prevalence surveys, and herbal pharmacology texts reframed integrative care for subsequent research[19][20][12][21]. Period 2003-2009: Surveys and trials mapped cross-cultural CAM diffusion[22][23][24][25][26][27][28][29][30][31], pediatric decisions[32][33][34][35][36][37], oncology gaps[23][26][28][31], and trial methodology[38][39][40][41]. Benchmark prevalence studies[42], translational curcumin reviews[43][44], diabetes herb surveys[45], and acupuncture trial standards[41] shaped subsequent integrative research. Period 2010-2016: Researchers cataloged ethnobotanical plants, mapped herb-drug safety, and standardized acupuncture trials across clinical contexts[46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61]. Influential guidelines and reviews shaped trial rigor, oncology communication, cardiovascular safety, and indigenous pharmacopoeias[51][52][55][62][63]. Period 2017-2023: Surveys, trials, and TCM frameworks evaluated herbal adjuvants for COVID-19 and chronic diseases while identifying sociodemographic drivers of complementary medicine uptake[64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82]. Reporting guidelines, chemoecological insights, pandemic evidence appraisals, and immunomodulatory reviews shaped subsequent rigorous CAM research and clinical integration[83][84][64][85].

Mainstreaming and Evidence-Based Integrative Medicine era

Richard L. Nahin and Patricia M. Barnes

Richard L. Nahin[1], conducting research at the National Institutes of Health[3] and the National Center for Complementary and Integrative Health[4], mapped cross-cultural usage patterns and pediatric care dynamics through population studies. This work was established by publishing Complementary and alternative medicine use among adults: United States, 2002[8] and Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007[7], which quantified national trends to support evidence-based integration. Patricia M. Barnes[2], based at the National Center for Health Statistics[5] and the Centers for Disease Control and Prevention[6], co-authored these population-level assessments. Through the papers Complementary and alternative medicine use among adults: United States, 2002[8] and Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007[7], this research charted widespread public utilization of integrative therapies to inform clinical and public health responses.